See more : Festaria Holdings Co., Ltd. (2736.T) Income Statement Analysis – Financial Results
Complete financial analysis of SHL Telemedicine Ltd. (SHLT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SHL Telemedicine Ltd., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- EDOM Technology Co., Ltd. (3048.TW) Income Statement Analysis – Financial Results
- 8i Acquisition 2 Corp. (LAXXW) Income Statement Analysis – Financial Results
- Citra Nusantara Gemilang Tbk. (CGAS.JK) Income Statement Analysis – Financial Results
- CTS International Logistics Corporation Limited (603128.SS) Income Statement Analysis – Financial Results
- Arise AB (publ) (ARISE.ST) Income Statement Analysis – Financial Results
SHL Telemedicine Ltd. (SHLT)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.shl-telemedicine.com
About SHL Telemedicine Ltd.
SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. The company offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; Cardio'B, a portable device to transmit a 12-lead ECG; and Cardio Beeper 12/12, a hand-held ECG transmitter device for personal use that transmits a full ECG reading to the monitoring center. It also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices; TeleWeight, a trans-telephonic weight monitoring device for personal use; TelePress, a remote blood pressure monitoring device for personal use; TeleBreather, a remote electronic handheld device to test the working of lungs; and TelePulse Oximeter, an electronic handheld diagnostic device to measure the saturation level of oxygen in blood, as well as pulse rate. The company offers its telemedicine services and devices to subscribers using telephonic and internet communication technology. It serves patients, health insurance companies, hospitals, clinics, physicians, and other health care providers. The company has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and collaboration agreement with the Hebrew University of Jerusalem and the Hadassah Medical Center to develop an artificial intelligence tool for predicting future life-threatening cardiac events based on 12 Lead ECG monitoring. SHL Telemedicine Ltd. was founded in 1987 and is headquartered in Tel Aviv, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 57.08M | 59.00M | 49.58M | 40.16M | 41.88M | 48.86M | 37.38M | 40.55M | 34.58M | 39.98M | 29.67M | 26.94M | 42.37M | 50.25M | 47.89M | 44.55M | 62.12M | 62.85M | 99.05M | 103.05M | 98.78M | 89.80M |
| Cost of Revenue | 31.81M | 31.81M | 24.99M | 19.52M | 18.42M | 18.65M | 17.79M | 19.48M | 20.56M | 17.71M | 13.73M | 12.63M | 15.39M | 14.69M | 13.52M | 12.79M | 29.57M | 30.14M | 54.40M | 58.40M | 52.13M | 44.05M |
| Gross Profit | 25.26M | 27.19M | 24.59M | 20.64M | 23.46M | 30.21M | 19.59M | 21.07M | 14.02M | 22.26M | 15.94M | 14.31M | 26.98M | 35.56M | 34.37M | 31.76M | 32.55M | 32.70M | 44.65M | 44.65M | 46.66M | 45.75M |
| Gross Profit Ratio | 44.26% | 46.08% | 49.60% | 51.40% | 56.02% | 61.83% | 52.42% | 51.96% | 40.55% | 55.69% | 53.72% | 53.10% | 63.68% | 70.76% | 71.77% | 71.29% | 52.40% | 52.04% | 45.08% | 43.33% | 47.23% | 50.95% |
| Research & Development | 5.26M | 3.79M | -431.00K | -360.00K | 2.51M | 173.00K | -981.00K | -1.11M | -1.00M | -1.31M | -1.60M | -1.48M | 1.33M | 1.60M | 1.22M | 1.00M | 2.55M | 911.00K | 915.00K | 712.00K | 672.00K | 415.00K |
| General & Administrative | 20.36M | 20.83M | 3.95M | 3.93M | 2.83M | 2.65M | 2.54M | 4.75M | 3.47M | 3.00M | 2.99M | 3.47M | 11.91M | 10.95M | 10.14M | 11.53M | 14.92M | 9.67M | 33.97M | 32.84M | 32.72M | 26.68M |
| Selling & Marketing | 3.19M | 3.57M | 2.81M | 1.82M | 1.20M | 1.05M | 1.25M | 1.66M | 2.46M | 2.88M | 2.12M | 2.01M | 9.57M | 14.75M | 14.04M | 12.16M | 12.61M | 10.91M | 13.88M | 12.81M | 10.20M | 7.01M |
| SG&A | 23.55M | 24.39M | 6.76M | 5.75M | 4.03M | 3.70M | 3.79M | 6.42M | 5.92M | 5.88M | 5.12M | 5.48M | 21.48M | 25.69M | 24.18M | 23.69M | 27.53M | 20.58M | 47.85M | 45.65M | 42.92M | 33.68M |
| Other Expenses | 5.45M | -416.00K | -430.00K | -501.00K | -273.00K | 633.00K | 3.28M | 0.00 | -2.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 34.27M | 31.94M | 24.54M | 19.70M | 17.75M | 18.37M | 18.31M | 22.06M | 23.57M | 21.12M | 21.33M | 19.96M | 22.81M | 27.29M | 27.72M | 27.52M | 42.69M | 32.40M | 44.18M | 46.36M | 43.59M | 34.10M |
| Cost & Expenses | 66.08M | 63.75M | 49.53M | 39.22M | 36.17M | 37.02M | 36.10M | 41.53M | 44.13M | 38.83M | 35.07M | 32.59M | 38.20M | 41.98M | 41.24M | 40.31M | 72.27M | 62.54M | 98.58M | 104.76M | 95.71M | 78.15M |
| Interest Income | 1.05M | 429.00K | 376.00K | 104.00K | 22.00K | 134.00K | 122.00K | 332.00K | 126.00K | 503.00K | 811.00K | 824.00K | 4.65M | 1.32M | 1.85M | 8.20M | 1.41M | 601.00K | 1.07M | -60.74K | 0.00 | 0.00 |
| Interest Expense | 1.56M | 1.03M | 529.00K | 405.00K | 292.00K | 328.00K | 1.12M | 2.55M | 594.00K | 925.00K | 1.51M | 1.76M | 4.03M | 1.25M | 1.11M | 12.61M | 6.85M | 4.86M | 5.66M | 4.16M | 0.00 | 0.00 |
| Depreciation & Amortization | 7.69M | 7.11M | 5.39M | 4.96M | 3.93M | 3.97M | 4.55M | 5.66M | 6.34M | 6.08M | 4.83M | 4.27M | 4.73M | 5.40M | 4.78M | 7.14M | 8.73M | 8.65M | 4.58M | 0.00 | 0.00 | 0.00 |
| EBITDA | 3.28M | 2.14M | -7.25M | 5.41M | 9.22M | 15.95M | 8.82M | -520.75K | -8.58M | 8.85M | 7.87M | -583.76K | 10.71M | 12.70M | 12.95M | 11.38M | 45.74M | 9.71M | 469.00K | -1.71M | 3.07M | 11.66M |
| EBITDA Ratio | 5.75% | 3.62% | -14.78% | 13.20% | 22.05% | 33.56% | 23.73% | 12.19% | -16.69% | 20.40% | -1.58% | -2.33% | 31.98% | 25.27% | 27.04% | 25.54% | 73.44% | 15.44% | 0.47% | -1.66% | 3.11% | 12.98% |
| Operating Income | -9.01M | -5.17M | -497.00K | 396.00K | 4.77M | 11.99M | 4.10M | -4.79M | -15.39M | 1.29M | 3.10M | -5.65M | 4.17M | 5.98M | 6.65M | 4.24M | -10.14M | 305.00K | -4.12M | -1.71M | 3.07M | 11.66M |
| Operating Income Ratio | -15.78% | -8.76% | -1.00% | 0.99% | 11.39% | 24.53% | 10.97% | -11.82% | -44.50% | 3.22% | 10.44% | -20.99% | 9.85% | 11.91% | 13.89% | 9.52% | -16.33% | 0.49% | -4.15% | -1.66% | 3.11% | 12.98% |
| Total Other Income/Expenses | 3.04M | 6.48M | -12.97M | -319.00K | -309.00K | -522.00K | -1.09M | -2.41M | -383.00K | 567.00K | -1.56M | -1.02M | 617.00K | 68.00K | 408.00K | -5.47M | 40.29M | -4.10M | 3.99M | -6.71M | -10.33M | 1.76M |
| Income Before Tax | -5.96M | 1.31M | -13.47M | 77.00K | 4.77M | 11.47M | 3.01M | -7.20M | -15.77M | 1.85M | 1.54M | -6.68M | 4.79M | 6.05M | 7.06M | -1.23M | 30.15M | -3.79M | -127.00K | -5.04M | -1.66M | 13.42M |
| Income Before Tax Ratio | -10.45% | 2.22% | -27.17% | 0.19% | 11.39% | 23.46% | 8.06% | -17.75% | -45.61% | 4.64% | 5.19% | -24.78% | 11.30% | 12.04% | 14.74% | -2.76% | 48.53% | -6.04% | -0.13% | -4.89% | -1.68% | 14.94% |
| Income Tax Expense | 891.00K | 1.10M | 455.00K | -201.00K | -923.00K | 1.32M | 606.00K | 3.90M | 863.00K | 1.02M | -693.00K | 628.00K | 792.00K | 1.19M | -1.68M | 3.46M | 6.50M | -412.00K | -7.42M | 318.00K | -1.02M | -3.23M |
| Net Income | -7.06M | -76.00K | -14.11M | 278.00K | 5.70M | 10.14M | 2.41M | -11.10M | -16.64M | 829.00K | 2.23M | -7.30M | 4.00M | 4.86M | 5.38M | 2.23M | 23.38M | -8.46M | -7.55M | -4.72M | -10.20M | 1.41M |
| Net Income Ratio | -12.36% | -0.13% | -28.46% | 0.69% | 13.60% | 20.75% | 6.44% | -27.37% | -48.10% | 2.07% | 7.52% | -27.11% | 9.43% | 9.67% | 11.23% | 5.01% | 37.63% | -13.47% | -7.62% | -4.58% | -10.32% | 1.57% |
| EPS | -0.43 | -0.01 | -1.00 | 0.03 | 0.54 | 0.97 | 0.23 | -1.06 | -1.59 | 0.08 | 0.22 | -0.70 | 0.38 | 0.46 | 0.51 | 0.21 | 2.20 | -0.80 | -0.71 | -0.45 | -0.96 | 0.13 |
| EPS Diluted | -0.43 | -0.01 | -1.00 | 0.03 | 0.54 | 0.96 | 0.23 | -1.06 | -1.59 | 0.08 | 0.22 | -0.69 | 0.38 | 0.46 | 0.51 | 0.21 | 2.16 | -0.80 | -0.71 | -0.45 | -0.96 | 0.13 |
| Weighted Avg Shares Out | 16.27M | 14.54M | 14.05M | 10.50M | 10.50M | 10.50M | 10.49M | 10.49M | 10.48M | 10.45M | 10.37M | 10.48M | 10.52M | 10.52M | 10.58M | 10.58M | 10.62M | 10.62M | 10.67M | 10.57M | 10.59M | 10.63M |
| Weighted Avg Shares Out (Dil) | 16.27M | 14.54M | 14.05M | 10.50M | 10.50M | 10.52M | 10.50M | 10.49M | 10.48M | 10.56M | 10.46M | 10.52M | 10.52M | 10.58M | 10.58M | 10.58M | 10.81M | 10.62M | 10.67M | 10.57M | 10.59M | 10.63M |
SHL Telemedicine Confirms Discussions Regarding a Possible Investment in its Israeli Activity
SHL Telemedicine Expands Offering in Israel With Groundbreaking At-home Biomarker Blood Test
SHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft Launch
SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones
Imperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine's SmartHeart® in Post-ACS Patient Care
SHL Telemedicine's SmartHeart® Technology Triumphs in US Army Project Convergence – Capstone 4 Experiment
SHL Telemedicine: Invitation to Conference Call Presenting Annual Results 2023
SHL Telemedicine Receives Buy Rating with $11.00 Price Target
Imperial College London TELE-ACS Clinical Trial Results, Using SHL Telemedicine's SmartHeart® Technology, to Be Presented at ACC 24
SHL Telemedicine and BARMER to Highlight Digital Patient Care at BMC Congress 2024
Source: https://incomestatements.info
Category: Stock Reports